Skip to main content
. 2018 Jul 24;29(10):2052–2060. doi: 10.1093/annonc/mdy264

Table 1.

Select baseline characteristics in the intention-to-treat population

Characteristics Avelumab Chemotherapy
(n =185) (n =186)
Age, median (range), years 59 (29–86) 61 (18–82)
Sex
 Male 140 (75.7) 127 (68.3)
 Female 45 (24.3) 59 (31.7)
ECOG PS
 0 66 (35.7) 62 (33.3)
 1 119 (64.3) 124 (66.7)
Histology
 Tubular 67 (36.2) 66 (35.5)
 Signet ring 42 (22.7) 36 (19.4)
 Mucinous 15 (8.1) 21 (11.3)
 Papillary 3 (1.6) 5 (2.7)
 Other 57 (31.3) 58 (31.2)
 Missing 1 (0.5) 0
Tumour site
 Gastric 122 (65.9) 138 (74.2)
 Gastro-oesophageal junction 63 (34.1) 48 (25.8)
Geographic region
 Europe 111 (60.0) 114 (61.3)
 Asia 46 (24.9) 47 (25.3)
 North America 14 (7.6) 11 (5.9)
 Rest of the world 14 (7.6) 14 (7.5)
Race
 White 119 (64.3) 117 (62.9)
 Asian 47 (25.4) 47 (25.3)
 Black 1 (0.5) 1 (0.5)
 Not collected/missing 18 (9.7) 21 (11.4)
Time since diagnosis of metastatic disease, median (range), months 13.6 (2–106) 13.9 (3–64)
Number of prior anticancer therapies for locally advanced/metastatic disease
 1a 26 (14.1) 22 (11.8)
 2 158 (85.4) 161 (86.6)
 3 0 1 (0.5)
 ≥4 0 0
 Missing 0 2 (1.1)
PD-L1 status, ≥1% staining threshold on tumour cells
 Positive 46 (29.3) 39 (24.4)
 Negative 111 (70.7) 121 (75.6)

Data are number of patients (%) unless specified otherwise.

a

Patients who progressed on neoadjuvant therapy without receiving surgery or adjuvant therapy within 6 months of treatment discontinuation were considered to have received one line of prior treatment of advanced, inoperable disease.

ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death ligand-1.